224 related articles for article (PubMed ID: 32350906)
1. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
Guasch M; Cañete F; Ordás I; Iglesias-Flores E; Clos A; Gisbert JP; Taxonera C; Vera I; Mínguez M; Guardiola J; Rivero M; Nos P; Gomollón F; Barrio J; de Francisco R; López-Sanromán A; Martín-Arranz MD; Garcia-Planella E; Camargo R; García-López S; de Castro L; Calvet X; Esteve M; Mañosa M; Domènech E;
J Gastroenterol Hepatol; 2020 Dec; 35(12):2080-2087. PubMed ID: 32350906
[TBL] [Abstract][Full Text] [Related]
2. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
3. How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort.
Ott C; Takses A; Obermeier F; Schnoy E; Salzberger B; Müller M
Int J Colorectal Dis; 2014 Nov; 29(11):1329-38. PubMed ID: 25179426
[TBL] [Abstract][Full Text] [Related]
4. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.
Ljung T; Karlén P; Schmidt D; Hellström PM; Lapidus A; Janczewska I; Sjöqvist U; Löfberg R
Gut; 2004 Jun; 53(6):849-53. PubMed ID: 15138212
[TBL] [Abstract][Full Text] [Related]
5. Use of Anti-TNFα Agents and Time to First-time Surgery in Paediatric Patients with Ulcerative Colitis and Crohn's Disease.
Larsen MD; Qvist N; Nielsen J; Kjeldsen J; Nielsen RG; Nørgård BM
J Crohns Colitis; 2016 Jun; 10(6):650-6. PubMed ID: 26802081
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
[TBL] [Abstract][Full Text] [Related]
7. Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.
Olbjørn C; Rove JB; Jahnsen J
Paediatr Drugs; 2020 Aug; 22(4):409-416. PubMed ID: 32378002
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
9. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.
Ananthakrishnan AN; Sakuraba A; Barnes EL; Pekow J; Raffals L; Long MD; Sandler RS
Aliment Pharmacol Ther; 2017 Jul; 46(2):162-168. PubMed ID: 28470787
[TBL] [Abstract][Full Text] [Related]
10. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
11. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
[TBL] [Abstract][Full Text] [Related]
12. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.
Pariente B; Laharie D
Aliment Pharmacol Ther; 2014 Aug; 40(4):338-53. PubMed ID: 24957164
[TBL] [Abstract][Full Text] [Related]
13. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study.
Charpentier C; Salleron J; Savoye G; Fumery M; Merle V; Laberenne JE; Vasseur F; Dupas JL; Cortot A; Dauchet L; Peyrin-Biroulet L; Lerebours E; Colombel JF; Gower-Rousseau C
Gut; 2014 Mar; 63(3):423-32. PubMed ID: 23408350
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.
Brady JE; Stott-Miller M; Mu G; Perera S
Clin Ther; 2018 Sep; 40(9):1509-1521.e5. PubMed ID: 30126706
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressant medications and mortality in inflammatory bowel disease.
Lewis JD; Gelfand JM; Troxel AB; Forde KA; Newcomb C; Kim H; Margolis DJ; Strom BL
Am J Gastroenterol; 2008 Jun; 103(6):1428-35; quiz 1436. PubMed ID: 18494836
[TBL] [Abstract][Full Text] [Related]
16. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases.
Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Avlund S; Olesen TB; Green A; Hoffmann HJ; Thomsen MK; Thomsen VØ; Nexø BA; Vogel U; Andersen V
Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748864
[TBL] [Abstract][Full Text] [Related]
18. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients.
Simian D; Fluxá D; Flores L; Lubascher J; Ibáñez P; Figueroa C; Kronberg U; Acuña R; Moreno M; Quera R
World J Gastroenterol; 2016 Jun; 22(22):5267-75. PubMed ID: 27298570
[TBL] [Abstract][Full Text] [Related]
20. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.
Hiroz P; Vavricka SR; Fournier N; Safroneeva E; Pittet V; Rogler G; Schoepfer AM;
Scand J Gastroenterol; 2014 Oct; 49(10):1207-18. PubMed ID: 25120029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
